Pharming Group's Strong 2024 Financial Results and Future Growth

Author: Lucas Young Updated: 03-13-2025 02:16 AM

Pharming Group Reports Strong Financial Results for 2024

Leiden, the Netherlands: Pharming Group N.V. (Euronext Amsterdam: PHARM / Nasdaq: PHAR) is excited to share its financial report for the year 2024, showcasing impressive growth in revenues and a successful business strategy.

Financial Highlights

In 2024, Pharming achieved total revenues of US$297.2 million, marking a 21% increase from the previous year. This surge in revenue was primarily fueled by record sales of RUCONEST® and remarkable growth of Joenja® (leniolisib), which saw a revenue increase of 147% following its launch.

The fourth quarter also showcased positive trends, with total revenues reaching US$92.7 million, representing a 14% increase from the fourth quarter of the prior year. Pharming recorded operating profits of $6.7 million, up significantly from $1.1 million in the same quarter last year.

Product Performance

RUCONEST® Sales Surge

RUCONEST®, Pharming's flagship product for treating acute Hereditary Angioedema (HAE) attacks, reported full-year revenues of US$252.2 million, an 11% increase compared to the previous year. This growth is reflected by strong demand and an expanding prescriber base, with over 100 new patients enrolled in the fourth quarter alone.

Joenja® Soars Post-Launch

Following its launch in early 2023, Joenja® achieved notable revenues of US$45 million in 2024. The fourth quarter alone brought in US$13.1 million as more patients accessed this innovative treatment for APDS (Activated PI3K Delta Syndrome).

Strategic Business Developments

Pharming has made significant strides this year, including the acquisition of Abliva AB. This acquisition adds KL1333 to Pharming's product pipeline, targeting mitochondrial DNA-driven primary mitochondrial diseases. This strategic move aligns with Pharming's vision of becoming a leading global rare disease company.

CEO Fabrice Chouraqui expressed his excitement about leading the company, emphasizing the impressive financial results and the ongoing efforts to advance key products in their pipeline. With regulatory reviews for leniolisib ongoing, Pharming is poised to reach a larger patient population.

Future Outlook

Looking ahead to 2025, Pharming has set a revenue target of between US$315 million and US$335 million, indicating continued growth and a focus on expanding Joenja® access, especially in international markets.

The company remains committed to investing in research and development, particularly to broaden the indications for leniolisib and advance clinical trials for other primary immunodeficiencies. Pharming is also progressing through key regulatory submissions aimed at maximizing the potential of their rare disease treatments.

Frequently Asked Questions

What were Pharming's total revenues for 2024?

Pharming's total revenues for 2024 reached US$297.2 million, a 21% increase from the prior year.

How did RUCONEST® perform in 2024?

RUCONEST® recorded full-year revenues of US$252.2 million, an 11% increase compared to 2023, driven by strong demand and a growing patient base.

What was Joenja®'s revenue in its first full year?

Joenja® generated revenues of US$45 million in 2024, reflecting a 147% increase compared to 2023.

What strategic acquisition did Pharming make in 2024?

Pharming acquired Abliva AB, incorporating KL1333 into its product pipeline to target mitochondrial DNA-driven diseases.

What is the revenue guidance for Pharming in 2025?

For 2025, Pharming anticipates total revenues between US$315 million and US$335 million, demonstrating optimism for continued growth.

About The Author

Even at just 28 years old, Lucas Young has made a name for himself as a writer and financial expert. Lucas is a gifted communicator of difficult financial ideas and has written a number of well-received books and articles that appeal to both new and experienced investors. The financial world has come to rely on his perceptive analysis and useful counsel. Many people have been enabled to make wise investment decisions by Lucas's commitment to financial literacy and his ability to demystify the complexities of the market. Lucas is still dedicated to advising and teaching people on their financial journeys as he shares his knowledge.

Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.